Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy-Reference-Cited by-同舟云学术

Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy

Published:2021-12 Issue: Volume:165 Page:44-51
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Liu Kevin X.,Sierra-Davidson Kailan,Tyan Kevin,Orlina Lawrence T.,Marcoux J. Paul,Kann Benjamin H.,Kozono David E.,Mak Raymond H.,White Abby,Singer Lisa

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference40 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

2. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805;Albain;J Clin Oncol,1995

3. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group;Sugarbaker;J Thorac Cardiovasc Surg,1995

4. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial;Albain;Lancet,2009

5. Induction treatment before surgery for non-small cell lung cancer;Eberhardt;Lung Cancer,2003

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment;Tuberculosis and Respiratory Diseases;2024-07-01

2. The analysis of current international recommendations for the treatment of patients with stage III non-small cell lung cancer;Grekov's Bulletin of Surgery;2024-05-19

3. Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment;Journal of Thoracic Oncology;2023-09